Literature DB >> 2041951

Risk factors for candidemia in patients with acute lymphocytic leukemia.

H M Richet1, A Andremont, C Tancrede, J L Pico, W R Jarvis.   

Abstract

Between 1983 and 1987 the overall incidence of candidemia at the Institut Gustave Roussy, a tertiary care referral hospital for patients with cancer, increased from 0.1% (7 of 6,801) to 0.32% (24 of 7,515) (P = .009). Because acute lymphocytic leukemia (ALL) was the most common underlying disease in patients with candidemia, risk factors for candidemia were analyzed in this subset of patients. A case-control study comparing the eight ALL patients who had candidemia with 18 ALL control patients revealed that previous bacteremia, prolonged neutropenia, prolonged fever, prolonged administration of antimicrobial agents, treatment with multiple antimicrobial agents, and a relatively high concentration of Candida organisms in stool were significant risk factors for candidemia. In a logistic regression analysis, however, only receipt of vancomycin and/or imipenem was identified as an independent risk factor for candidemia. Further analysis showed that administration of vancomycin promoted proliferation of Candida organisms in the gastrointestinal tract and that this proliferation was associated with an increased risk of candidemia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2041951     DOI: 10.1093/clinids/13.2.211

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  31 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 2.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

3.  Emerging Issues in Nosocomial Fungal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

Review 4.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 5.  Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.

Authors:  J L Vincent; E Anaissie; H Bruining; W Demajo; M el-Ebiary; J Haber; Y Hiramatsu; G Nitenberg; P O Nyström; D Pittet; T Rogers; P Sandven; G Sganga; M D Schaller; J Solomkin
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

6.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Authors:  Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

7.  An experimental model for study of Candida survival and transmission in human volunteers.

Authors:  M S Rangel-Frausto; A K Houston; M J Bale; C Fu; R P Wenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

8.  Prophylactic use of fluconazole in neutropenic cancer patients.

Authors:  K Yamaç; E Senol; R Haznedar
Journal:  Postgrad Med J       Date:  1995-05       Impact factor: 2.401

9.  Unexpected candidemia complicating ureteroscopy and urinary stenting.

Authors:  M Gross; H Winkler; S Pitlik; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

10.  Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection.

Authors:  S Takakura; N Fujihara; T Saito; T Kudo; Y Iinuma; S Ichiyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.